Nestle Health Science and DBV Technologies to collaborate on pediatric milk allergy test

Epalinges / CH. (nsa) Nestle Health Science announced that it has entered into a strategic collaboration with DBV Technologies, headquartered in Montrouge, France, aimed at developing and bringing to market DBV’s innovative patch-test tool for the diagnosis of Cow’s Milk Protein Allergy (CMPA) in infants.

CMPA is a difficult to diagnose condition, which impacts up to 2-3 percent of infants and young children during a critical stage of their development. DBV will leverage its proprietary «Viaskin» technology platform to develop an innovative, ready-to-use, standardized atopy patch-test.

Today, CMPA is often missed in the primary care settings due to the non-specific nature of symptoms associated with the condition, such as eczema, reflux, constipation, diarrhea, crying and others. In 2015, Nestle Health Science made a first step forward in addressing this difficulty through the Cow’s Milk-related Symptom Score («CoMiSS») awareness tool, developed by leading international experts to help healthcare professionals earlier recognize and assess symptoms that may be related to CMPA in infants and young children.

In the future, DBV’s patch-test will enable early and accurate diagnosis of the condition, leading to early nutritional intervention, thereby creating a strong fit with Nestle Health Science’s nutritional solutions that helps meet the needs of babies and children with food allergies and intolerances.

Under the terms of the agreement, DBV grants Nestle Health Science exclusive worldwide commercialization rights of DBV’s diagnostic tool. Nestle Health Science will make an upfront payment of 10 million EUR. DBV will be responsible for the development stages, including industrialization and regulatory submissions. Moreover, DBV is eligible to receive development milestones, and if approved, sales milestones and royalty payments on sales.

Greg Behar, CEO of Nestle Health Science, said: «This innovation can become the breakthrough diagnostic for CMPA. Early diagnosis and nutritional intervention helps get infants happily back on the path of healthy development, alleviate the anxieties of parents, and reduce healthcare costs. Our reach in the field of pediatric allergy makes Nestle Health Science an ideal commercialization partner for DVB’s innovative diagnostic patch. This collaboration is another step in our strategy of advancing the role of nutrition through science-based innovation».

DBV Technology’s Chief Executive Officer, Dr. Pierre-Henri Benhamou, said, «Improving the lives of those suffering from food allergies is DBV’s mission, and through this exciting partnership with Nestle Health Science, we are further showcasing our portfolio of potentially transformational and cutting-edge products. Combining DBV’s innovative and proprietary technology with Nestle Health Science’s global presence and expertise in nutritional therapies is a synergistic approach that we believe has the potential to improve the overall health of our patients».